Wire · opportunities
Novel CAR-T therapy for hard-to-treat multiple myeloma shows promising safety and ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
A Phase 1 clinical trial of anito-cel, a novel BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma, demonstrated high response rates with durable benefits and minimal severe neurological side effects. The therapy is advancing to Phase 2 and 3 trials to validate these promising safety and efficacy results.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can pursue CAR-T therapies with better safety profiles as this new treatment avoids severe neurological side effects seen in older methods. If your biotech venture focuses on multiple myeloma, now is the moment to explore partnerships or research in novel engineered CAR-T domains.
◆ Coverage
1 source · 25 Sep 2026
◆ Related on Wire
◆ Topics